BIRMINGHAM, Ala. & NEW YORK--(BUSINESS WIRE)--DiscoveryBioMed, Inc. (DBM) and Mount Sinai School of Medicine (MSSM) have agreed to move forward on multiple “fee for service” contracts in human cell optimization, assay optimization and pilot drug discovery bioassays on behalf of the Mount Sinai Office of Technology and Business Development (OTBD) and MSSM investigators.
